RA-18) is developed in rabbit using as
immunogen a synthetic peptide corresponding to amino
acids 394-411 of human MBD2a conjugated to KLH via
an N-terminal added lysine residue. This sequence is
conserved
-207.
Feany, M. and Bender, W. (2000). A Drosophila model of Parkinson's disease. Nature 404
: 394-398.
Mirabella, N., et al. (2000). The distribution and co-localization of nicotine adenine
dinucleotide
associated with invasiveness and
unfavorable prognosis in breast cancer. Am J Clin
Pathol., 105, 394–402 (1996).
10. Yoshiura, K. et al., Silencing of the E-cadherin
invasion-suppressor gene by CpG
523 001
MagNA Pure LC RNA Isolation Kit -
High Performance
1 kit, up to 192 isolations 03 542 394 001
Protector RNase Inhibitor 2,000 U, 40 U/μl 03 335 399 001
10,000 U, 5 x 2,000 U
591 001
MagNA Pure LC RNA Isolation Kit –
High Performance
1 kit, up to 192 isolations 03 542 394 001
RealTime ready Cell Lysis Kit 1 kit, 50 lysis reactions with a final reaction
volume of 40
apoptosis with ApopTag®
Peroxidase and for necrosis using trypan blue has been described (29).
TECH NOTE #6: Silanized slides
In order to avoid detachment of tissue sections during processing
apoptosis with ApopTag®
Peroxidase and for necrosis using trypan blue has been described (29).
TECH NOTE #6: Silanized slides
In order to avoid detachment of tissue sections during processing
058519.3 ,NP_058525.1 y y y
491 Nerve Growth Factor-β N3279 4803 NGF M NP 002497 y y n/d
394 N Ki J4500 MAPK8 P
709 phospho-Tau (pSer199/202) T6819 4137 MAPT P
058519.3 ,NP_058525.1 y y y
491 Nerve Growth Factor-β N3279 4803 NGF M NP 002497 y y n/d
394 N Ki J4500 MAPK8 P
709 phospho-Tau (pSer199/202) T6819 4137 MAPT P
058519.3 ,NP_058525.1 y y y
491 Nerve Growth Factor-β N3279 4803 NGF M NP 002497 y y n/d
394 N Ki J4500 MAPK8 P
709 phospho-Tau (pSer199/202) T6819 4137 MAPT P
gene expression in response to
mechanical strain in osteoblastic cells. Biochem Biophys
Res Commun 394, 755, 2010.
119. Meyer, U., et al. Strain-related bone remodeling in distrac-
tion osteogenesis
PAK (p21-Activated Kinase)
Monoclonal Antibody
Anti-PAK1, Rab Mab H M R IF IP WB IH(P) 100 µL 04-394
Anti-PAK3, Rab Mab H M R IF IP WB IH(P) Rb IgG 100 µL 04-395
Polyclonal Antibody
Anti-PAK3
NATURAL, 98%, FCC W214019 A29284 HC-23SI2U44
393. BENZYL CINNAMATE 98% W214205 B46260 HC-23SIB466
394. BENZYL DISULFIDE 98% W361704 A55831 HC-23SIUN13
This is to certify that the following product(s
NATURAL, 98%, FCC W214019 A29284 HC-22SI2K65
393. BENZYL CINNAMATE 98% W214205 B46260 HC-22SI8387
394. BENZYL DISULFIDE 98% W361704 A55831 HC-22SIYN34
This is to certify that the following product(s
Applications Format Host Quantity Cat. No.
Antibody
Anti-PAK1, Rb Mab H M R IF IP WB IH(P) 100 µL 04-394
Anti-PAK3, Rb Mab H M R IF IP WB IH(P) Rb IgG 100 µL 04-395
Anti-PAK3
y y y
393 JAK 1 J3774 84598, 3716, 16451 Jak1,JAK1 XP_342873.3,NP_002218.2,NP_666257.2 M y n/d n/d
394 c-Jun N-Terminal Kinase J4500 5599, 26419, 116554 Mapk8,MAPK8 NP_620637.1,NP_057909.1,XP_341400.3 P